Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory hurdles, and operational challenges. Read more on VOR.

Vor Biopharma Inc. (NASDAQ:VOR) is one of the hot penny stocks to invest in now. In a report released on June 30, Swayampakula Ramakanth from H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ ...

As of May 8, PureTech held a 2.1% beneficial ownership stake in Vor Bio, reflecting its founding role in the company. According to Benzinga Pro, VOR stock has lost over 30% in the past year.

Vor Biopharma (NASDAQ:VOR) stock tumbles as plans to find strategic alternatives lead to downgrades on Wall Street firms, Stiflel and Baird. Read more here.